Browsing by Author "Okella, Hedmon"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Dioscorea bulbifera, a highly threatened African medicinal plant, a review
    (a review, Cogent Biology, 2019) Ikiriza, Hilda; Engeu Ogwang, Patrick; Peter, Emanuel L.; Okella, Hedmon; Umba Tolo, Casim; Muwonge, Abubaker; Mai Abdalla, Ali Abdalla
    Dioscorea bulbifera bulbils are used in the treatment of Piles, dysentery, syphilis, ulcers, cough, leprosy, diabetes, asthma, and cancer. It is a raw material for contraceptives, and it is one of the most consumed yam species especially in West Africa. Unfortunately, this plant is at the verge of extinction because of increased harvest for medicinal purpose. This review aims at providing up-to-date information about its photochemistry, clinical benefits, conservation status and best possible way on how this plant can be conserved for future use. Literature database search was employed, and the findings indicate that much as Dioscorea bulbifera is of diverse clinical and ethnomedicinal benefits, it’s vulnerable to extinction. In order to conserve Dioscorea bulbifera, there is a need to enlighten the local inhabitants on its clinical and commercial importance and uses. Also for the sustainable growth of the plant, the government and Non-governmental agencies have to distribute Dioscorea bulbils to the farmers for planting and also encourage its planting back into the wild. In addition, micropropagation of the D. bulbifera will be the perfect tool for reestablishing the plant in the natural habitat with more advantages of improving growth conditions of the plants.
  • Thumbnail Image
    Item
    Retrospective in silico mutation profiling of SARS-CoV-2 structural proteins circulating in Uganda by July 2021: Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics
    (Plos one, 2022) Odongo, Steven; Okella, Hedmon; Ndekezi, Christian; Okee, Moses; Namayanja, Monica; Mujuni, Brian; Sterckx, Yann G. J.; Kizito, Dennison; Mwiine, Frank Nobert; Lutwama, Julius Julian; Ibingira, Charles
    The SARS-CoV-2 virus, the agent of COVID-19, caused unprecedented loss of lives and economic decline worldwide. Although the introduction of public health measures, vaccines, diagnostics, and therapeutics disrupted the spread of the SARS-CoV-2, the emergence of variants poses substantial threat. This study traced SARS-CoV-2 variants circulating in Uganda by July 2021 to inform the necessity for refinement of the intervention medical products. A comprehensive in silico analysis of the SARS-CoV-2 genomes detected in clinical samples collected from COVID-19 patients in Uganda revealed occurrence of structural protein variants with potential of escaping detection, resisting antibody therapy, or increased infectivity. The genome sequence dataset was retrieved from the GISAID database and the open reading frame encoding the spike, envelope, membrane, or nucleocapsid proteins was translated. The obtained protein sequences were aligned and inspected for existence of variants. The variant positions on each of the four alignment sets were mapped on predicted epitopes as well as the 3D structures. Additionally, sequences within each of the sets were clustered by family. A phylogenetic tree was constructed to assess relationship between the encountered spike protein sequences and Wuhan-Hu-1 wild-type, or the Alpha, Beta, Delta and Gamma variants of concern. Strikingly, the frequency of each of the spike protein point mutations F157L/Del, D614G and P681H/R was over 50%. The furin and the transmembrane serine protease 2 cleavage sites were unaffected by mutation. Whereas the Delta dominated the spike sequences (16.5%, 91/550), Gamma was not detected. The envelope protein was the most conserved with 96.3% (525/545) sequences being wild-type followed by membrane at 68.4% (397/580). Although the nucleocapsid protein sequences varied, the variant residue positions were less concentrated at the RNA binding domains. The dominant nucleocapsid sequence variant was S202N (34.5%, 205/595). These findings offer baseline information required for refining the existing COVID-19 vaccines, diagnostics, and therapeutics.